Theradex Oncology has announced the release of their proprietary clinical trial management system (CTMS) that provides real-time access to analytics allowing for maximum study visibility for enhanced informed decisions.
After 35 years of partnering with the National Cancer Institute (NCI) and all 49 NCI-designated Comprehensive Cancer Centers, Theradex Oncology is now releasing its CTMS to existing clients. This system provides a solution with to support oncology studies of all types, sizes, phases, and complexities.
"We are in a highly evolving and heavily regulated marketplace, which can be extremely challenging for many of our clients. Our CTMS system acknowledges those challenges by integrating a user-friendly, highly competent, end-to-end user platform that increases crucial insights that our clients have never had before," stated Susan Davey, vice president of technology, Theradex Oncology.